On Friday, a wave of selling pressure swept across the US equity markets, leaving a trail of losses. The S&P 500 closed down ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

Johnson & Johnson’s stock rose 1.1% on Thursday, reaching $159.56. Trading volume dropped significantly, with 1.7 million ...

As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one ...

Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...

We recently published a list of 10 Best DRIP Stocks To Own Now. In this article, we are going to take a look at where Johnson ...

We recently published a list of 11 Best Performing Dow Stocks So Far in 2025. In this article, we are going to take a look at ...

As of 20 February 2025, the index has steadily increased, rising 14.41% in the last 12 months and 4.21% year to date in 2025.

Johnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults with ...

Sanctuary Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 10.4% during the fourth quarter, ...

Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...

NEWARK, CA / ACCESS Newswire / February 21, 2025 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today reported financial results for the fourth quarter and full year ended ...